Science5 days ago
Regeneron Reports Strong Phase 3 Results for Rare Disorder Treatment
Regeneron Pharmaceuticals Inc. announced promising results from its Phase 3 OPTIMA trial of garetosmab, a potential treatment for adults suffering from fibrodysplasia ossificans progressiva (FOP), a...